Tag Archives: Aurinia Pharmaceuticals

Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More

If you’re keeping track, FDA drug approvals have been on a tear in the past month with several decisions coming well ahead of their targeted dates. And then there’s Sarepta Therapeutics. Late Thursday, the FDA announced approval of the Cambridge, MA, biotech’s drug for Duchenne muscular dystrophy in patients who have a specific mutation. The […]

Aurinia Plans FDA Filing After Lupus Nephritis Drug Hits Phase 3 Goals

Aurinia shares spiked last week after voclosporin, an immunosuppressant being tested in patients with lupus nephritis, met its primary and secondary endpoints in a Phase 3 study. Aurinia Pharmaceuticals (NASDAQ: AUPH) is testing its drug, voclosporin, as a treatment for lupus nephritis (LN), which can occur when lupus, an autoimmune disorder, causes the immune system […]

Posted in National, National blog main | Tagged Aurinia Pharmaceuticals, Biotech, immunosuppressants, Life Sciences, Lupus nephritis | Comments Off

Oyster Point Gets $93M To Clear Up Dry Eye With a Nasal Spray

Dry eye disease affects millions of people in the U.S., and while several treatments, mostly eye drops, are available, they all have flaws. An emerging startup called Oyster Point Pharmaceuticals is trying a completely different approach—a nasal spray that coaxes the body into making tears. And the company just got enough cash to get that […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, New York, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories | Tagged Allergan, American Journal of Ophthalmology, Aurinia Pharmaceuticals, Catalyst Biosciences, Chantix, cyclosporine, deals, dry eye disease, Jeffrey Nau, Life Sciences, lifitegrast, New Enterprise Associates, nicotinic acetylcholine receptors, Ophthotech, Oyster Point Pharmaceuticals, Restasis, Shire, startups, Targacept, TrueTear, varenicline, VC, Versant Ventures, Xiidra | Comments Off

Bio Roundup: FDA Says No, PCSK9 Value Fight, CRISPR Intrigue & More

When the Olympics roll around, many watchers get into a sport they previously hadn’t thought much about. This time for me, it’s volleyball. The men’s and women’s games, both indoor and beach versions, are fast, aggressive, with lightning-quick adjustments and subtle teamwork required every time a ball is dug out and popped in the air. […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Wisconsin blog main, Wisconsin top stories | Tagged abaloparatide, Agios Pharmaceuticals, Amgen, Andexxa, Andrew Hirsch, Approval, Aurinia Pharmaceuticals, Avelas Biosciences, bankruptcy, Bind Therapeutics, Biotech, Chiasma, CRISPR, CRISPR-Cas9, Cystic Fibrosis, Editas Medicine, FDA, Feng Zhang, Hair Regrowth, Histogen, Immunotherapy, Ivacaftor, Jennifer Doudna, Juno Therapeutics, lawsuit class action, Life Sciences, lumacaftor, Lupus nephritis, MIT Technology Review, Olympics, Osteoporosis, PCSK9, Pfizer, Phase 3, Portola Pharmaceuticals, Radius Health, Regeneron Pharmaceuticals, Rejections, Rio, Rivervest Venture Partners, Romosuzumab, Shuailiang Lin, Tioma therapeutics, Vertex Pharmaceuticals, voclosporin, VX-661 | Comments Off

Amid String of Exits for VenBio, a Founding Partner Leaves, Too

With three acquisitions of its portfolio companies, San Francisco biotech investment firm venBio has had a few good exits recently. Now one of its partners is exiting, too. Kurt Von Emster, one of four venBio founders, has decamped for Abingworth, a life science venture firm with a much longer history and global reach. Abingworth made […]

Posted in National blog main, San Diego blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged Aragon Pharamceuticals, Aurinia Pharmaceuticals, Biotech, Corey Goodman, Cytos Biotechnology, Kurt von Emster, Labrys Biologics, Life Sciences, Seragon Pharmaceuticals, Solstice Biologics, Steve Dowdy, VC, VenBio, Venture Capital | Comments Off

As Its Investors Reap Returns, venBio Aims for a Bigger Second Fund

San Francisco life sciences venture firm venBio is making news these days with entrances and exits. Since its $180 million inaugural fund closed in 2011, two of its portfolio companies have become splashy acquisitions, including one last week. Thanks to those exits, venBio’s investors have more than broken even, and the group is now eyeing […]

Posted in National blog main, National top stories, San Diego blog main, San Diego top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged Amgen, Aragon Pharamceuticals, Aspreva Pharmaceuticals, Aurinia Pharmaceuticals, Baxter International, Bob Adelman, Corey Goodman, Cytos Biotechnology, Heart Metabolics, Johnson & Johnson, Kurt von Emster, Labrys Biologics, Life Sciences, Limited Partners, Lou Tartaglia, LPs, Medivation, Paul Cooke, Pfizer, PPD, Prostate Cancer, Recapitalization, Rinat Neuroscience, Robert Adelman, Seragon Pharmaceuticals, Solstice Biologics, Teva Pharmaceutical Industries, VC, VenBio, Venture Capital | Comments Off